Novartis maintains growth momentum; Confirms FY’22 Group guidance
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Both the partners will work towards bringing Aster Pharmacy’s in-house quality care products to serve the healthcare needs of the local population in KSA
The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
This will dramatically improve timely intervention with the right experts thus ensuring significant improvement in patient’s condition management and health outcome
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
Monetary awards worth Rs 1.20 crore were presented amongst the winners for their remarkable contributions
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Subscribe To Our Newsletter & Stay Updated